Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.8K Buy
1,985
+329
+20% +$1.94K ﹤0.01% 3043
2026
Q1
$6.81K Sell
1,656
-262
-14% -$1.27K ﹤0.01% 3246
2025
Q4
$12.8K Buy
1,918
+1,403
+272% +$9.5K ﹤0.01% 2864
2025
Q3
$3.16K Buy
515
+60
+13% +$468 ﹤0.01% 3324
2025
Q2
$4.19K Sell
455
-1,093
-71% -$11.2K ﹤0.01% 3186
2025
Q1
$18.6K Buy
1,548
+550
+55% +$7.19K ﹤0.01% 2422
2024
Q4
$11K Sell
998
-86
-8% -$1.21K ﹤0.01% 2555
2024
Q3
$17.6K Buy
1,084
+597
+123% +$8.35K ﹤0.01% 2184
2024
Q2
$5.28K Buy
487
+9
+2% +$111 ﹤0.01% 2552
2024
Q1
$6.69K Buy
478
+88
+23% +$1.14K ﹤0.01% 2267
2023
Q4
$4.95K Buy
+390
New +$3.49K ﹤0.01% 2248

Other funds holding EOLS

GAMMA Investing's EOLS Position: Q2 2026 in Review

GAMMA Investing increased its Evolus (EOLS) stake by 20% in Q2 2026, buying an estimated $1.94K and bringing the position to 1,985 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3043.

GAMMA Investing first reported a position in EOLS in Q4 2023 and has held it in 11 quarters since. The position peaked at $18.6K in Q1 2025. 15 funds tracked by Wall St. Rank hold EOLS as of Q2 2026.

  • GAMMA Investing held 1,985 shares of Evolus worth $13.8K as of Q2 2026.
  • GAMMA Investing bought 329 Evolus shares in Q2 2026, an estimated $1.94K.
  • Evolus made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3043 holding.
  • GAMMA Investing first reported a position in Evolus in Q4 2023 and has held it in 11 quarters since.
  • GAMMA Investing's Evolus position peaked at $18.6K in Q1 2025.
  • 15 funds tracked by Wall St. Rank held Evolus as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.